Cytopia adds and subtracts

By Dylan Bushell-Embling
Thursday, 10 July, 2008

Cytopia [ASX: CYT] has appointed Anadys Pharmaceuticals founder Dr Devron Averett as the company's new scientific advisor.

Averett has a Ph.D in microbiology and immunology and is an inventor of 17 current and nine pending US patents. He has had previous roles with Glaxo Wellcome and Burroughs Wellcome.

His work contributed to the discovery of a number of oncology and anti-viral drug candidates, including Zeffix, Emtriva and Ziagen.

The Melbourne-headquartered company has closed its New York office, losing business and corporate development VP Dr Shreefal Mehta, and will concentrate its US operations on California.

It has also appointed financial specialist Richard Haiduck as chief business advisor.

Related News

Cartherics and Catalent announce enhanced partnership

To support immune cell therapy products for the treatment of cancer and endometriosis, Australian...

Alliance seeks to boost regional capacity in clinical trials

Launched this week, the Barwon Health–Deakin University Clinical Trials Alliance is...

Lipid science receives new Australia-led online hub

The Lipid Network launched this month to build links between researchers, clinicians and industry...


  • All content Copyright © 2026 Westwick-Farrow Pty Ltd